Inhibition of highly pathogenic avian influenza (HPAI) virus by a peptide derived from vFLIP through its direct destabilization of viruses

[1]  Florian Krammer,et al.  An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin‐Bearing Influenza Viruses , 2017, Immunity.

[2]  V. Adam,et al.  Perspective of Use of Antiviral Peptides against Influenza Virus , 2015, Viruses.

[3]  R. Varadarajan,et al.  Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection , 2014, Proceedings of the National Academy of Sciences.

[4]  J. Taubenberger,et al.  Influenza Viruses: Breaking All the Rules , 2013, mBio.

[5]  N. S. Laursen,et al.  Broadly neutralizing antibodies against influenza viruses. , 2013, Antiviral research.

[6]  Antonio Lanzavecchia,et al.  Broadly neutralizing antiviral antibodies. , 2013, Annual review of immunology.

[7]  Jo Leonardi-Bee,et al.  Impact of Neuraminidase Inhibitor Treatment on Outcomes of Public Health Importance During the 2009–2010 Influenza A(H1N1) Pandemic: A Systematic Review and Meta-Analysis in Hospitalized Patients , 2012, The Journal of infectious diseases.

[8]  N. S. Laursen,et al.  Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.

[9]  F. Penin,et al.  Sublimable C5A Delivery Provides Sustained and Prolonged Anti-HIV Microbicidal Activities , 2012, Antimicrobial Agents and Chemotherapy.

[10]  P. Wilson,et al.  Targeting B cell responses in universal influenza vaccine design. , 2011, Trends in immunology.

[11]  G. Boivin,et al.  Influenza drug resistance. , 2011, Seminars in respiratory and critical care medicine.

[12]  D. Ekiert,et al.  Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes , 2010, Proceedings of the National Academy of Sciences.

[13]  John Steel,et al.  Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.

[14]  R. Hai,et al.  Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins , 2010, PLoS pathogens.

[15]  Shou-Jiang Gao,et al.  FLIP-mediated autophagy regulation in cell death control , 2009, Nature Cell Biology.

[16]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[17]  L. Nencioni,et al.  Therapeutic Activity of an Anti-Idiotypic Antibody-Derived Killer Peptide against Influenza A Virus Experimental Infection , 2008, Antimicrobial Agents and Chemotherapy.

[18]  Dennis R. Burton,et al.  Toward an AIDS Vaccine , 2008, Science.

[19]  Min-Chul Kim,et al.  Highly Pathogenic Avian Influenza Virus (H5N1) in Domestic Poultry and Relationship with Migratory Birds, South Korea , 2008, Emerging infectious diseases.

[20]  F. Chisari,et al.  A virocidal amphipathic α-helical peptide that inhibits hepatitis C virus infection in vitro , 2008, Proceedings of the National Academy of Sciences.

[21]  H Peltola,et al.  Vaccination greatly reduces disease, disability, death and inequity worldwide. , 2008, Bulletin of the World Health Organization.

[22]  Erik De Clercq,et al.  The design of drugs for HIV and HCV , 2007, Nature Reviews Drug Discovery.

[23]  John J Rossi,et al.  Genetic therapies against HIV , 2007, Nature Biotechnology.

[24]  W. Marasco,et al.  The growth and potential of human antiviral monoclonal antibody therapeutics , 2007, Nature Biotechnology.

[25]  S. Dowdy,et al.  TAT transduction: the molecular mechanism and therapeutic prospects. , 2007, Trends in molecular medicine.

[26]  K. Subbarao,et al.  Scientific barriers to developing vaccines against avian influenza viruses , 2007, Nature Reviews Immunology.

[27]  E. Turpin,et al.  Inhibition of Influenza Virus Infection by a Novel Antiviral Peptide That Targets Viral Attachment to Cells , 2006, Journal of Virology.

[28]  C. Coopersmith,et al.  TAT-BH4 and TAT-Bcl-xL Peptides Protect against Sepsis-Induced Lymphocyte Apoptosis In Vivo1 , 2006, The Journal of Immunology.

[29]  Steven F Dowdy,et al.  Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis , 2004, Nature Medicine.

[30]  E. Snyder,et al.  Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide , 2004, PLoS biology.

[31]  Feng Gao,et al.  Diversity Considerations in HIV-1 Vaccine Selection , 2002, Science.

[32]  M. Zasloff.  Antimicrobial peptides of multicellular organisms , 2002, Nature.

[33]  Warren Strober,et al.  Trypan Blue Exclusion Test of Cell Viability , 2001, Current protocols in immunology.

[34]  R. Hancock,et al.  Cationic peptides: a new source of antibiotics. , 1998, Trends in biotechnology.

[35]  T. F. Smith,et al.  Replication and plaque assay of influenza virus in an established line of canine kidney cells. , 1968, Applied microbiology.

[36]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[37]  Hao Wu,et al.  Structural studies of NF-κB signaling , 2011, Cell Research.

[38]  T. Laue,et al.  Analytical ultracentrifugation: sedimentation velocity and sedimentation equilibrium. , 2008, Methods in cell biology.

[39]  W. Strober.  Trypan blue exclusion test of cell viability. , 2001, Current protocols in immunology.

[40]  Y. Shai,et al.  Mode of action of linear amphipathic α-helical antimicrobial peptides , 1998 .

[41]  Petra Ostermann,et al.  Breaking all the rules , 1984, Nature.